Идёт
Фаза III
ДОСТАРЛИМАБ (TSR-042) · Тезаро, Инк. (Tesaro, Inc.)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)